Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals

• Autor(a) principal: Colombo, Arnaldo Lopes [UNIFESP]
• Data de Publicação: 2013
• Outros Autores: Garnica, Marcia, Camargo, Luís Fernando Aranha [UNIFESP], Da Cunha, Clovis Arns, Bandeira, Antonio Carlos, Borghi, Danielle, Campos, Tatiana, Senna, Ana Lucia, Didier, Maria Eugenia Valias, Dias, Viviane Carvalho, Nucci, Marcio
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.3109/13693786.2012.698024; http://repositorio.unifesp.br/handle/11600/35773
• topic: Candida glabrata; emergent fungal pathogen; fluconazole resistance; epidemiology

Candida glabrata is an infrequent cause of candidemia in Brazilian public hospitals. We investigated putative differences in the epidemiology of candidemia in institutions with different sources of funding. Prospective laboratory-based surveillance of candidemia was conducted in seven private and two public Brazilian tertiary care hospitals. Among 4,363 episodes of bloodstream infection, 300 were caused by Candida spp. (6.9%). Incidence rates were significantly higher in public hospitals, i.e., 2.42 vs. 0.91 episodes per 1,000 admissions (P < 0.01). Patients in private hospitals were older, more likely to be in an intensive care unit and to have been exposed to fluconazole before candidemia. Candida parapsilosis was more frequently recovered as the etiologic agent in public (33% vs. 16%, P < 0.001) hospitals, whereas C. glabrata was more frequently isolated in private hospitals (13% vs. 3%, P < 0.001). Fluconazole resistance among C. glabrata isolates was more frequent in private hospitals (76.5% vs. 20%, P = 0.02). the 30-day mortality was slightly higher among patients in public hospitals (53% vs. 43%, P = 0.10). Candida glabrata is an emerging pathogen in private institutions and in this setting, fluconazole should not be considered as a safe option for primary therapy of candidemia.